PepChile

Salud Intestinal, Microbioma y Función Digestiva

Categorías: Guías Prácticas, Salud Metabólica

Gut es segunda cerebro (enteric nervous system), y microbioma controla 70% immune system. Disbiosis (desequilibrio bacterial) ligada IBS, inflamación crónica, autoimmunity, metabolismo dysfunction. Péptidos restore barrier + optimize microbiota.

Resumen Simplificado

BPC-157 500mcg diario (barrier restoration, tight junction repair, acetylcholine—GI motility). LL-37 500mcg-1mg diario (dysbiosis breaking, pathogenic bacteria suppression, probiotic selection). GLP-1 bajo-dosis 0.25mg semanal (gut mucus layer enhancement, Akkermansia—beneficial bacteria). Probiotics synergy (Lactobacillus, Bifidobacterium multi-strain). Timeline: barrier function measurable 4-6 semanas (zonulin reduction), microbiota rebalance 8-12 semanas, symptom remisión (IBS, bloating) 6-12 semanas.

Leaky Gut and Barrier Dysfunction: BPC-157 Tight Junction Repair

GUT BARRIER = epithelial lining + tight junctions (claudins, occludin, ZO-1 proteins). LEAKY GUT (intestinal permeability meningkat): tight junctions loosen → bacterial lipopolysaccharide (LPS, endotoxin) bocor ke bloodstream → lipopolysaccharemia → systemic inflamasi → autoimmunity risk, allergies, dysbiosis. CAUSE LEAKY GUT: dysbiosis (pathogenic bacteria alter tight junction), inflamasi (TNF-alpha, IL-6 → tight junction protein degradation), NSAID use (damage epithelial lining), stress (cortisol), food intolerance (zonulin release dari gluten, gula refined). BPC-157 PRIMARIO: tight junction protein upregulation (claudin-2 expression increase, occludin protein synthesis enhance); acetylcholine agonist (meningkat submucosal cholinergic tone—vascular perfusion GI improve, epithelial regeneration accelerate). DOSIS: 500mcg diario inyectable o oral (beide effective, tapi oral dosing higher needed untuk systemic effect). MECANISME REPAIR: BPC-157 → neuronal growth factor (NGF) synthesis → epithelial progenitor cell proliferation → barrier renewal (epithelium turnover adalah 3-5 hari naturally, BPC accelerate ke 2-3 hari). TIMELINE: tight junction restoration measurable zonulin test (fasting serum zonulin baseline → 4-6 minggu post-BPC, expect 20-40% reduction); symptom improvement (bloating, gas, diarrhea) 2-4 minggu. TESTING BARRIER: zonulin (intestinal permeability marker), lipopolysaccharide (LPS, endotoxin), fecal lactoferrin (inflamasi marker).

Dysbiosis Reversal: LL-37 Pathogenic Suppression + Probiotic Enhancement

DYSBIOSIS = altered bacterial composition (pathogenic bacteria ↑, commensals ↓). PATHOGENIC BACTERIA: E. coli pathogenic (ETEC), Clostridium difficile, Staphylococcus aureus, Klebsiella—produce inflammation, LPS, dysbiosis-perpetuating factors. LL-37: antimicrobial peptido, SELECTIVE killing pathogens preferentially bahwa commensals (some commensal have LL-37 resistance mechanisms, sesuai evoluasi coexistence). DOSIS DYSBIOSIS: 500mcg-1mg intranasal o oral diario (12+ minggu untuk dysbiosis reversal, vs. 1-2 minggu infeksi akut). MECANISME LL-37 + MICROBIOTA: (1) pathogenic bacterial reduction; (2) commensal bacterial selection (niche opening untuk beneficial bacteria); (3) microbiota diversity increase (consequence ecological restoration). PROBIOTIC SYNERGY KRITIS: LL-37 + multi-strain probiotics (Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium longum) = LL-37 clear pathogens, probiotics colonize emptied niche. DOSIS PROBIOTICS: 25-100 billion CFU diario (multi-strain, 5-10 spesies), kontinyu 8-12 minggu minimal untuk establish. TIMELINE DYSBIOSIS: microbiota composition change measurable stool microbiota testing (16S rRNA gene sequencing baseline → 4 minggu, expect pathogenic bacterial reduction 30-50%; → 8 minggu, expect beneficial bacterial increase 50-100%, diversity increase). MONITORING: stool test microbiota (Viome, Everlywell, atau research lab).

Mucus Layer Enhancement: GLP-1 + Akkermansia muciniphila

GUT MUCUS LAYER = protection epithelial barrier (first line против luminal pathogens + antigens). MUCUS composition: mucin-2 (MUC2) protein, sekresi dari goblet cells. DYSBIOSIS erode mucus layer (pathogenic bacteria lipase, protease mendegrade mucin; beneficial bacteria produce short-chain fatty acids—butyrate, yang stimulate goblet cell → mucin production). GLP-1 AGONISTA: stimulasi goblet cell differentiation + MUC2 synthesis. DOSIS GLP-1: 0.25mg semanal (low—purely metabolic/mucus enhancement, bukan weight-loss dosis). MECANISME: GLP-1R expressed pada goblet cell precursor cells; activation → IL-22 production (intestinal epithelial-derived), JAK-STAT signaling → goblet cell maturation → MUC2 ↑. AKKERMANSIA MUCINIPHILA: beneficial bacteria, mucus-degrading (produce deacetylase, remove acetyl groups mucin, allow better barrier function paradoxically—degraded mucin stimulate regeneration goblet cell). GLP-1 selectively promote Akkermansia growth (mechanistic benefit terletak Akkermansia). DOSIS GLP-1 KOMBINASI: Semaglutida 0.25mg semanal (for mucus) + probiotic Akkermansia jika available (Akk.muciniphila spesific supplement—relative scarce komersial, tapi emerging supplement). TIMELINE MUCUS: fecal mucin concentration (proxy untuk mucus layer thickness) measurable 4-6 minggu, Akkermansia bloom (stool microbiota test) 2-4 minggu post-GLP-1 initiation. BENEFIT BEYOND MUCUS: Akkermansia metabolite propionate (short-chain fatty acid) → Treg differentiation (immune tolerance), reduced intestinal permeability (tight junction).

IBS, Colitis, dan Inflamatory Bowel Protocols

IBS (Irritable Bowel Syndrome) = functional disorder (pain, constipation/diarrhea alternating, no organic inflammation vs. IBD). PATHOPHYSIOLOGY IBS: dysbiosis, barrier dysfunction, visceral hypersensitivity, abnormal GI motility, low-grade inflamasi (elevated TNF-alpha, IL-6). PROTOKOL IBS: BPC-157 500mcg diario (barrier repair + acetylcholine → motility normalization) + LL-37 500mcg diario (dysbiosis reversal) + probiotics multi-strain + GLP-1 0.25mg weekly (mucus + AKK). TIMELINE IBS REMISYON: cramping/pain reduction 2-4 minggu (BPC acetylcholine effect), diarrhea/constipation normalization 4-8 minggu (microbiota rebalance), full remisyon 8-12 minggu (barrier restoration + microbiota + motility). COLITIS (ulceratif colitis, Crohn's disease) = inflamatory bowel disease (IBD), aktual epithelial ulceration. PROTOKOL COLITIS: BPC-157 500mcg-1mg diario (barrier repair, ulcer healing, epithelial regeneration—topical rectal enema + systemic inyectable) + LL-37 amplified (750mcg-1mg diario, dysbiosis major contributor IBD) + probiotics + GLP-1 0.25mg weekly + anti-inflamatori additional (Selank 250mcg intranasal untuk neuro-immune benefit, Thymosin Alpha-1 optional jika immune restoration needed). TIMELINE COLITIS: fecal calprotectin (inflamasi marker) reduction 4-8 minggu, endoscopic improvement (ulcer healing) 8-12 minggu, clinical remisyon 12-16 minggu (longer bahwa IBS karena tissue damage lebih severo). MONITOREO IBD: fecal calprotectin (quantitative fecal TNF-alpha), colonoscopy + biopsy (endoscopic remisyon assessment), CRP/ESR, vitamin B12/folate (malabsorption risk IBD).

Hallazgos Clave

Productos relacionados

Más artículos en Guías Prácticas

Más artículos en Salud Metabólica

Artículos relacionados

Preguntas frecuentes

¿Cuál es diferencia IBS vs. IBD treatment protocol peptido?
IBS = functional (no epithelial damage), fokus barrier function + motility + dysbiosis, BPC + LL-37 + GLP-1 sufficient. IBD = inflamasi aktual + ulceration, memerlukan more aggressive protocol: higher BPC dosis (500mcg-1mg), intensifikasi LL-37 (750mcg-1mg), tambah anti-inflamatori (Selank, thymosin), lebih lama duration (12-16 minggu vs. 8-12 IBS). Monitoreo IBD lebih frequent (fecal calprotectin monthly, colonoscopy periodic).
¿Puedo menggunakan probiotics dengan LL-37 secara bersamaan?
Ya, sinergi. LL-37 clears pathogenic niche, probiotics colonize hasil emptied niche. Timing optimal: LL-37 pagi, probiotics malam (atau spacing 3-4 jam) untuk maximal effect. LL-37 tidak kill probiotics (selectivity untuk pathogenic vs. commensal maintained). Kombinasi LL-37 + probiotics superior mono-therapy untuk dysbiosis reversal.
¿Berapa lama continuity BPC-157 untuk leaky gut remisyon?
Biasanya 4-6 minggu untuk tight junction restoration (zonulin test measurable improvement). Tapi barrier durability requires ongoing—epithelium turnover 3-5 hari, jadi cycling recommended: 8-12 minggu ON, 2-4 minggu OFF (permite intestinal adaptation, reset tolerance). Jika chronic leaky gut atau recurrent triggers (NSAID, stress), maintenance long-term BPC (250mcg diario) dapat diterima.

Volver a la biblioteca de investigación